AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Oral Mucosal Absorption Study of Bicalutamide New Formulation
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- Drug: ICI176,334-1
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2011-08-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT01416883
Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 581
- Registration Number
- NCT01415518
- Locations
- 🇨🇳
Research Site, Huhehaote, China
Oral Mucosal Absorption of ICI176,334-1
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ICI176,334-1
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2012-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT01415791
Bioequivalence of ICI176,334-1 in Japanese Healthy Male Subjects
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2012-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT01415778
[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
Phase 3
Completed
- Conditions
- HypertriglyceridemiaCardiovascular Disease
- Interventions
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 646
- Registration Number
- NCT01408303
To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT01403922
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Budesonide/formoterol (Symbicort® Turbuhaler®)
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 793
- Registration Number
- NCT01397890
- Locations
- 🇹🇭
Research Site, Udon Thani, Thailand
Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate Response
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 545
- Registration Number
- NCT01397903
- Locations
- 🇬🇷
Research Site, Trikala, Greece
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Phase 4
Completed
- Conditions
- Gastroesophageal Reflux DiseaseGERDReflux Esophagitis
- Interventions
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 107
- Registration Number
- NCT01397084
A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT01396226
- Locations
- 🇸🇪
Research Site, Örebro, Sweden